IFNG and hepatocellular carcinoma: These reference T cell epitopes derived from hepatocellular carcinoma (HCC)-associated tumor antigens (HCC1-1, HCC1-2, HCC5-3, HCC5-4, and HCC5-5, restricted by HLA-A0201) or from hepatitis B virus antigens (HBV111 and HBV118, restricted by HLA-A2402) have previously been functionally validated in-house to be real-world epitopes because they can effectively stimulate the PBMCs of HCC or chronic hepatitis B patients to produce IFN-γ in an ex vivo 20-h ELISPOT assay and in vitro after costimulation (manuscript submitted).